During the first cycle, this T32 Program has functioned under the auspices of the Center for Drug Discovery (CDD) initially at the University of Connecticut (UConn) and more recently at Northeastern University (NU). All slots have been filled, and by summer of 2006 seven students will have received Ph.D. degrees. Of the postdoctoral fellows who have participated in the program, four have progressed to careers involving drug abuse research. In this proposed renewal we will continue to produce scientists trained in the multidisciplinary effort required to develop medications for drug abuse. This request for renewal of the Program at the same level of activity as our current grant includes 5 postdoctoral positions and 6 predoctoral student trainee slots, which will spend 2-3y and 4-5y, respectively, in the Program. Our primary objective is to familiarize trainees with the chemical, physiological, pharmacological, and clinical aspects of drug discovery and development in the field of drugs of abuse. Currently drug discovery is experiencing a major transformation initiated by the introduction of powerful new technologies. This training program is committed to cover this new terrain by providing trainees with novel coursework and the opportunity to train in leading academic laboratories. Their training is broadened by the participation of premier scientists and laboratories from the pharmaceutical and biotechnology industries. We have sought to include in our training faculty scientists with a strong record of accomplishment representing some of the novel technologies that have become an integral part of drug discovery. These include high throughput chemistry and screening, the use of mass spectrometry to study genomics, proteomics and metabolomics, NMR and x-ray crystallography to extend the study of target-based discovery as well as in vivo imaging. Predoctoral students will register at NU with affiliation to the CDD and will earn a Ph.D. in either Pharmaceutical Sciences or in Chemistry and Chemical Biology. Post-doctoral fellows training in areas including medicinal chemistry, structural and molecular biology, biochemical pharmacology, behavioral science, separations technologies (LC-MS), and in vivo imaging may chose mentored academic projects at any of the program sites. Relevance: Societal and medical problems involving substance abuse continue to plague the United States. Few medications are yet available to help health care professionals treat dependent and addicted individuals, and this area is badly underrepresented within the pharmaceutical industry. By training junior scientists, this Program seeks to address this deficiency.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
3T32DA007312-10S1
Application #
8656260
Study Section
Special Emphasis Panel (ZDA1-MXS-M (21))
Program Officer
Shih, Ming L
Project Start
1999-07-01
Project End
2014-06-30
Budget Start
2011-07-01
Budget End
2014-06-30
Support Year
10
Fiscal Year
2013
Total Cost
$96,804
Indirect Cost
$6,414
Name
Northeastern University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
001423631
City
Boston
State
MA
Country
United States
Zip Code
02115
Li, H; Wood, J T; Whitten, K M et al. (2013) Inhibition of fatty acid amide hydrolase activates Nrf2 signalling and induces heme oxygenase 1 transcription in breast cancer cells. Br J Pharmacol 170:489-505
Tian, Xiaoyu; Pavlopoulos, Spiro; Yang, De-Ping et al. (2011) The interaction of cannabinoid receptor agonists, CP55940 and WIN55212-2 with membranes using solid state 2H NMR. Biochim Biophys Acta 1808:2095-101
Duclos Jr, Richard I; Johnston, Meghan; Vadivel, Subramanian K et al. (2011) A methodology for radiolabeling of the endocannabinoid 2-arachidonoylglycerol (2-AG). J Org Chem 76:2049-55
Wood, Jodianne T; Williams, John S; Pandarinathan, Lakshmipathi et al. (2010) Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res 51:1416-23
Hwang, Jeannie; Adamson, Crista; Butler, David et al. (2010) Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci 86:615-23
Wood, JodiAnne T; Williams, John S; Pandarinathan, Lakshmipathi et al. (2008) Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin Chem Lab Med 46:1289-95
Guo, Jianxin; Yang, De-Ping; Chari, Ravi et al. (2008) Magnetically aligned bicelles to study the orientation of lipophilic ligands in membrane bilayers. J Med Chem 51:6793-9
Zvonok, Nikolai; Pandarinathan, Lakshmipathi; Williams, John et al. (2008) Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol 15:854-62
Tian, Xiaoyu; Guo, Jianxin; Yao, Fenmei et al. (2005) The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J Biol Chem 280:29788-95